Michael Heathman, M.S.

Group Leader PKPD, Senior Principal Scientist I

Michael brings over 30 years of experience in the pharmaceutical industry. Prior to joining Metrum Research Group in 2018, he was Head of Global Pharmacometrics at Eli Lilly and Company, where he led efforts to apply PK/PD modeling and simulation to all phases of drug development. He has extensive experience in the application of pharmacometrics to support quantitative decision making across a broad range of disease states and therapeutic areas.

Recent publications by this scientist

The Effect of CYP2B6 Genotype on the Clearance and Autoinduction of Efavirenz in Healthy Subjects and the Subsequent Impact on Efavirenz Exposure

December 6, 2024

Presented at ACoP 2024. Efavirenz is metabolized primarily by CYP2B6, to form 8-OH EFV, and also by CYP2A6, to form 7-OH EFV. Upon chronic administration, efavirenz induces both CYP2B6 and CYP2A6, leading to autoinduction of its metabolism. A population pharmacokinetic model was constructed to quantify the impact of CYP2B6 phenotype on efavirenz autoinduction and subsequent exposure.

Download PDF

Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.

December 6, 2024

Presented at ACoP 2024. A longitudinal joint model of modified mayo scores and dropout for patients with ulcerative colitis receiving etrasimod was developed in two Phase 3 studies. This poster presents the development of the model in a Bayesian framework, illustrating the ability of the model to adequately describe changes in efficacy scores in the presence of a spike in dropout at the end of a maintenance phase.

Download PDF

Oral progesterone-mediated attenuation of ibutilide-induced qt interval lengthening in premenopausal and postmenopausal women: population pharmacokinetic/ pharmacodynamic model.

April 3, 2024

Presented at ASCPT Annual Meeting 2024. Our model adequately characterized ibutilide PK and its QT interval lengthening effect. The higher Emax suggests more ibutilide induced QT lengthening in premenopausal women. The difference of Emax between group A and B reflects potential progesterone effect.